For adults with type 2 diabetes and inadequate glycemic control, glycemic control improved with addition of tirzepatide versus placebo<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Feb. 10, 2022 (HealthDay News) — The addition of subcutaneous tirzepatide versus placebo to titrated insulin glargine results in significant improvements in glycemic control among patients with type 2 diabetes and inadequate glycemic control, according to a study published in the Feb. 8 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Dominik Dahl, M.D., from Gemeinschaftspraxis f \u00bcr Innere Medizin und Diabetologie in Hamburg, Germany, and colleagues randomly assigned adults with type 2 diabetes receiving insulin glargine, who had inadequate glycemic control, to receive once-weekly subcutaneous injections of 5-mg, 10-mg, or 15-mg tirzepatide (116, 119, and 120, respectively) or volume-matched placebo (120 adults) over 40 weeks.<\/p>\n The researchers found that treatment was discontinued prematurely by 10, 12, 18, and 3 percent of participants in the tirzepatide 5-mg, 10-mg, and 15-mg groups and placebo group, respectively. From baseline to week 40, the mean hemoglobin A1c (HbA1c) change was \u00e2\u0088\u00922.11, \u00e2\u0088\u00922.40, and \u00e2\u0088\u00922.34 percent with 5-mg, 10-mg, and 15-mg tirzepatide, respectively, versus \u00e2\u0088\u00920.86 percent with placebo. From baseline, the mean change in body weight was \u00e2\u0088\u00925.4, \u00e2\u0088\u00927.5, \u00e2\u0088\u00928.8, and 1.6 kg with 5-mg, 10-mg, and 15-mg tirzepatide and placebo, respectively. Compared with those treated with placebo, higher percentages of patients treated with tirzepatide had HbA1c less than 7 percent (85 to 90 percent versus 34 percent).<\/p>\n “The results from the current study provide clinically relevant information relative to the use of tirzepatide in combination with a basal insulin that should be of help to clinicians when this treatment option is considered,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n